FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308174573> ?p ?o ?g. }

• W4308174573 abstract "Abstract Background The reimbursement for expensive medicines poses a growing challenge to healthcare worldwide. In order to increase its control over the costs of medicines, the Dutch government introduced the Coverage Lock (CL) policy in 2015. The CL postpones decisions regarding reimbursement of expensive medicines until detailed advice on i.e., cost-effectiveness has been given. The CL has been in place for six years, has raised many questions and concerns, but currently, no evaluation is known to the authors. A better understanding of the effects of the CL on all stakeholders involved may contribute to reflections on the CL process and help find ways to improve it. An evaluation of Dutch policy will also be relevant for other countries that aim to optimize reimbursement procedures for expensive treatments. To perform this evaluation, we focused on the CL procedure for the medicine nusinersen. Nusinersen is the first treatment for spinal muscular atrophy (SMA). Following EMA approval in May 2017, it was placed in the CL. The analysis of cost-effectiveness and added therapeutic value resulted in an advice for reimbursement limited to children younger than 9.5 years at the start of treatment; this was implemented from August 2018 onwards. Methods Qualitative stakeholder perspective analysis of the CL procedure focusing on nusinersen with 15 stakeholders. Results Stakeholders raised key issues of the CL based on their experience with nusinersen: emotional impact of the CL, duration of the CL procedure, appropriateness of the CL procedure for different types of medicines, transparency of the CL, a wish for patient-centred decision-making and the lack of uniformity of access to expensive treatments. Discussion Stakeholders supported measures to control healthcare expenses and to ensure reasonable pricing. They considered the delay in access to therapies and lack of procedural transparency to be the main challenges to the CL. Stakeholders also agreed that the interests of patients deserve more attention in the practical implementation of the reimbursement decision. Stakeholders suggested a number of adjustments to improve the CL, such as a faster start with conditional reimbursement programs to ensure access and intensify European collaboration to speed up the assessment of the medicine." @default.
• W4308174573 created "2022-11-08" @default.
• W4308174573 creator A5011769862 @default.
• W4308174573 creator A5030545055 @default.
• W4308174573 creator A5044591358 @default.
• W4308174573 creator A5054183430 @default.
• W4308174573 creator A5059507602 @default.
• W4308174573 creator A5069378678 @default.
• W4308174573 creator A5074280458 @default.
• W4308174573 creator A5074561732 @default.
• W4308174573 date "2022-11-04" @default.
• W4308174573 modified "2023-10-09" @default.
• W4308174573 title "The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy" @default.
• W4308174573 cites W1566718566 @default.
• W4308174573 cites W1816608481 @default.
• W4308174573 cites W2037896483 @default.
• W4308174573 cites W2059998071 @default.
• W4308174573 cites W2093589847 @default.
• W4308174573 cites W2131080517 @default.
• W4308174573 cites W2144128138 @default.
• W4308174573 cites W2161078130 @default.
• W4308174573 cites W2212454316 @default.
• W4308174573 cites W2239306219 @default.
• W4308174573 cites W2416057499 @default.
• W4308174573 cites W2416145228 @default.
• W4308174573 cites W2579663022 @default.
• W4308174573 cites W2747792808 @default.
• W4308174573 cites W2765483614 @default.
• W4308174573 cites W2789114047 @default.
• W4308174573 cites W2884486468 @default.
• W4308174573 cites W2946967649 @default.
• W4308174573 cites W3004233329 @default.
• W4308174573 cites W3013371597 @default.
• W4308174573 cites W3036447492 @default.
• W4308174573 cites W3046295661 @default.
• W4308174573 cites W3109077683 @default.
• W4308174573 cites W3160726731 @default.
• W4308174573 cites W3172587796 @default.
• W4308174573 cites W3175127321 @default.
• W4308174573 cites W324102958 @default.
• W4308174573 cites W4223493443 @default.
• W4308174573 doi "https://doi.org/10.1186/s12913-022-08690-z" @default.
• W4308174573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36333803" @default.
• W4308174573 hasPublicationYear "2022" @default.
• W4308174573 type Work @default.
• W4308174573 citedByCount "0" @default.
• W4308174573 crossrefType "journal-article" @default.
• W4308174573 hasAuthorship W4308174573A5011769862 @default.
• W4308174573 hasAuthorship W4308174573A5030545055 @default.
• W4308174573 hasAuthorship W4308174573A5044591358 @default.
• W4308174573 hasAuthorship W4308174573A5054183430 @default.
• W4308174573 hasAuthorship W4308174573A5059507602 @default.
• W4308174573 hasAuthorship W4308174573A5069378678 @default.
• W4308174573 hasAuthorship W4308174573A5074280458 @default.
• W4308174573 hasAuthorship W4308174573A5074561732 @default.
• W4308174573 hasBestOaLocation W43081745731 @default.
• W4308174573 hasConcept C138885662 @default.
• W4308174573 hasConcept C160735492 @default.
• W4308174573 hasConcept C162324750 @default.
• W4308174573 hasConcept C17744445 @default.
• W4308174573 hasConcept C199539241 @default.
• W4308174573 hasConcept C201305675 @default.
• W4308174573 hasConcept C2778137410 @default.
• W4308174573 hasConcept C2779703844 @default.
• W4308174573 hasConcept C2780233690 @default.
• W4308174573 hasConcept C39549134 @default.
• W4308174573 hasConcept C41895202 @default.
• W4308174573 hasConcept C50522688 @default.
• W4308174573 hasConcept C512399662 @default.
• W4308174573 hasConcept C71924100 @default.
• W4308174573 hasConceptScore W4308174573C138885662 @default.
• W4308174573 hasConceptScore W4308174573C160735492 @default.
• W4308174573 hasConceptScore W4308174573C162324750 @default.
• W4308174573 hasConceptScore W4308174573C17744445 @default.
• W4308174573 hasConceptScore W4308174573C199539241 @default.
• W4308174573 hasConceptScore W4308174573C201305675 @default.
• W4308174573 hasConceptScore W4308174573C2778137410 @default.
• W4308174573 hasConceptScore W4308174573C2779703844 @default.
• W4308174573 hasConceptScore W4308174573C2780233690 @default.
• W4308174573 hasConceptScore W4308174573C39549134 @default.
• W4308174573 hasConceptScore W4308174573C41895202 @default.
• W4308174573 hasConceptScore W4308174573C50522688 @default.
• W4308174573 hasConceptScore W4308174573C512399662 @default.
• W4308174573 hasConceptScore W4308174573C71924100 @default.
• W4308174573 hasFunder F4320321007 @default.
• W4308174573 hasFunder F4320327989 @default.
• W4308174573 hasIssue "1" @default.
• W4308174573 hasLocation W43081745731 @default.
• W4308174573 hasLocation W43081745732 @default.
• W4308174573 hasLocation W43081745733 @default.
• W4308174573 hasLocation W43081745734 @default.
• W4308174573 hasOpenAccess W4308174573 @default.
• W4308174573 hasPrimaryLocation W43081745731 @default.
• W4308174573 hasRelatedWork W2029504117 @default.
• W4308174573 hasRelatedWork W2033336193 @default.
• W4308174573 hasRelatedWork W2127306072 @default.
• W4308174573 hasRelatedWork W2136065980 @default.
• W4308174573 hasRelatedWork W2196132342 @default.
• W4308174573 hasRelatedWork W2540965855 @default.
• W4308174573 hasRelatedWork W2549077999 @default.

• next